Discover a groundbreaking advancement in treating Autosomal Recessive Deafness 9 (ARD9) with Dr. Yilai Shu, a pioneer in gene therapy for hearing loss. This webinar delves into the innovative AAV1-hOTOF gene therapy trial, offering new hope for individuals with ARD9, a condition characterized by severe bilateral hearing loss from birth due to mutations in the OTOF gene.

Dr. Shu will share insights from the trial’s development to its promising outcomes, highlighting the safety and effectiveness of this novel treatment. The session includes an interactive Q&A, providing a deeper understanding of gene therapy’s potential to change lives for those affected by genetic hearing loss.

Ideal for healthcare professionals, researchers, and families impacted by ARD9, this webinar offers a glimpse into the future of hearing loss treatment through the lens of gene therapy.

On-demand video


4/24/2024 10:00 am EST/ 7:00am PST


Dr. Yilai Shu
Name: Dr. Yilai Shu
Company: Eye & ENT Hospital of Fudan University, Shanghai
Title: Medical Doctor
Dr. Yilai Shu, a preeminent figure in the field of otorhinolaryngology, embodies excellence in medical research and patient care. His role as Professor and Chief Physician at the Department of Otorhinolaryngology, Fudan University Affiliated Eye & ENT Hospital since December 2022 marks a significant milestone in a career that commenced with a foundational Bachelor of Clinical Medicine degree from Nanhua University. His academic journey is distinguished by an integrated Master’s and Ph.D. from Fudan University, and a joint Ph.D. program at Harvard Medical School and Massachusetts Eye and Ear Infirmary, reflecting his dedication to medical advancement and a fervent quest for knowledge.

Dr. Shu’s scholarly contributions are remarkable, with over 86 SCI papers to his name, including more than 60 as first or corresponding author in globally renowned journals. His groundbreaking work in genetic deafness gene therapy, particularly through collaborative efforts with notable figures such as David Liu and Zheng-Yi Chen, has pioneered new therapeutic avenues. His research achievements have earned him prestigious recognitions, including the National Science Fund for Distinguished Young Scholars. Dr. Shu holds influential positions in key medical and scientific societies, driving forward the discourse in otorhinolaryngology on both national and international stages. His dedication to advancing healthcare through innovation and research underscores his profound impact on the medical community and patient care worldwide.

Related services:


Express Gene to AAV Service

Comprehensive AAV production from gene to virus at unparalleled speed


[Video] Webinar: Treating Autosomal Recessive Deafness 9 with AAV1-hOTOF Gene Therapy